Preclinical AD predicts decline in memory and executive functions in subjective complaints

Neurology

Volumn 81, Issue 16, 2013, Pages 1409-1416

  Van Harten, Argonde C ^a   Smits, Lieke L ^a,b   Teunissen, Charlotte E ^b   Visser, Pieter J ^a,b,c   Koene, Teddy ^a,b   Blankenstein, Marinus A ^b   Scheltens, Philip ^a,b   Van Der Flier, Wiesje M ^a,b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; ATTENTION; CEREBROSPINAL FLUID; EDUCATIONAL STATUS; EXECUTIVE FUNCTION; FEMALE; FOLLOW UP; HOSPITAL PATIENT; HUMAN; LANGUAGE; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; MEMORY; MINI MENTAL STATE EXAMINATION; NEUROLOGIC EXAMINATION; PRIORITY JOURNAL; PSYCHOLOGIC TEST;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; COGNITION DISORDERS; DISEASE PROGRESSION; EXECUTIVE FUNCTION; FEMALE; HUMANS; MALE; MEMORY DISORDERS; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PREDICTIVE VALUE OF TESTS; PRODROMAL SYMPTOMS; PROGNOSIS; TAU PROTEINS;

EID: 84888217049     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182a8418b     Document Type: Article

References (40)

1. Benito-León J, Mitchell AJ, Vega S, Bermejo-Pareja F. A population-based study of cognitive function in older people with subjective memory complaints. J Alzheimers Dis 2010;22:159-170.
2. Reisberg B, Shulman MB, Torossian C, Leng L, Zhu W. Outcome over seven years of healthy adults with and without subjective cognitive impairment. Alzheimers Dement 2010;6:11-24.
3. Scheef L, Spottke A, Daerr M, et al. Glucose metabolism, gray matter structure, and memory decline in subjective memory impairment. Neurology 2012;79:1332-1339.
4. Flicker C, Ferris SH, Reisberg B. A longitudinal study of cognitive function in elderly persons with subjective memory complaints. J Am Geriatr Soc 1993;41:1029-1032.
5. Reid LM, Maclullich AM. Subjective memory complaints and cognitive impairment in older people. Dement Geriatr Cogn Disord 2006;22:471-485.
6. Antonell A, Fortea J, Rami L, et al. Different profiles of Alzheimer's disease cerebrospinal fluid biomarkers in controls and subjects with subjective memory complaints. J Neural Transm 2011;118:259-262.
7. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:280-292.
8. Visser PJ, Verhey F, Knol DL, et al. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: A prospective cohort study. Lancet Neurol 2009;8:619-627.
9. van Harten AC, Visser PJ, Pijnenburg YA, et al. Cerebrospinal fluid Abeta42 is the best predictor of clinical progression in patients with subjective complaints. Alzheimers Dement Epub 2012 Dec 8.
10. Peters KR, Lynn Beattie B, Feldman HH, Illes J. A conceptual framework and ethics analysis for prevention trials of Alzheimer disease. Prog Neurobiol Epub 2013 Jan 21.
11. Rami L, Fortea J, Bosch B, et al. Cerebrospinal fluid biomarkers and memory present distinct associations along the continuum from healthy subjects to AD patients. J Alzheimers Dis 2011;23:319-326.
12. Rolstad S, Berg AI, Bjerke M, et al. Amyloid-beta42 is associated with cognitive impairment in healthy elderly and subjective cognitive impairment. J Alzheimers Dis 2011;26:135-142.
13. Rolstad S, Berg AI, Bjerke M, Johansson B, Zetterberg H, Wallin A. Cerebrospinal fluid biomarkers mirror rate of cognitive decline. J Alzheimers Dis 2013;34:949-956.
14. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
15. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303-308.
16. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:263-269.
17. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging- Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7: 270-279.
18. Lindeboom J, Schmand B, Tulner L, Walstra G, Jonker C. Visual association test to detect early dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry 2002;73:126-133.
19. Rey A. l'Examen Clinique en Psychologie (The Clinical Examination in Psychology), 2nd ed. Paris: Presse Universitaire de France; 1964.
20. Saan RJ, Deelman BG. De 15-woorden test A en B: Een voorlopige handleiding (intern raport) (in Dutch). Groningen: Afdeling Neuropsychologie AZG; 1986.
21. Lindeboom J, Matto D. [Digit series and Knox cubes as concentration tests for elderly subjects.] Tijdschr Gerontol Geriatr 1994;25:63-68.
22. Reitan RM. Validity of the TrailMaking Test as indicator of organic brain damage. Percept Mot Skills 1958;8:271-276.
23. Benton AL, Hamsher K. Multilingual Aphasia Examination, 2nd ed. Iowa City: AJA Associates; 1989.
24. Luteijn F, van der Ploeg FAE. GIT: Groninger Intelligentie Test (in Dutch). Lisse: Swets & Zeitlinger; 1982.
25. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
26. Mulder C, Verwey NA, van der Flier WM, et al. Amyloidbeta( 1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin Chem 2010;56:248-253.
27. Knopman DS, Jack CR, Wiste HJ, et al. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology 2012;78:1576-1582.
28. Jack CR, Knopman DS, Weigand SD, et al. An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol 2012;71:765-775.
29. Crawford C, Tennstedt T, McKinlay M. A comparison of analytic methods for non-random missingness of outcome data. J Clin Epidemiol 1995;48:209-219.
30. Verhage F. Intelligence and Age: Study With Dutch People Aged 12-77 (in Dutch). Assen: Van Gorcum; 1964.
31. Jack CR, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9:119-128.
32. Glodzik L, De Santi S, Tsui WH, et al. Phosphorylated tau 231, memory decline and medial temporal atrophy in normal elders. Neurobiol Aging 2011;32:2131-2141.
33. Gustafson DR, Skoog I, Rosengren L, Zetterberg H, Blennow K. Cerebrospinal fluid beta-amyloid 1-42 concentration may predict cognitive decline in older women. J Neurol Neurosurg Psychiatry 2007;78:461-464.
34. Stomrud E, Hansson O, Blennow K, Minthon L, Londos E. Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly. Dement Geriatr Cogn Disord 2007;24:118-124.
35. Hulstaert F, Blennow K, Ivanoiu A, et al. Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology 1999;52:1555-1562.
36. Solé-Padullés C, Lladó A, Bartrés-Faz D, et al. Association between cerebrospinal fluid tau and brain atrophy is not related to clinical severity in the Alzheimer's disease continuum. Psychiatry Res 2011;192:140-146.
37. Dik MG, Deeg DJ, Bouter LM, Corder EH, Kok A, Jonker C. Stroke and apolipoprotein E epsilon4 are independent risk factors for cognitive decline: A populationbased study. Stroke 2000;31:2431-2436.
38. Meijer WA, van Boxtel MP, Van Gerven PW, van Hooren SA, Jolles J. Interaction effects of education and health status on cognitive change: A 6-year follow-up of the Maastricht Aging Study. Aging Ment Health 2009;13: 521-529.
39. Mol ME, van Boxtel MP, Willems D, Jolles J. Do subjective memory complaints predict cognitive dysfunction over time? A six-year follow-up of the Maastricht Aging Study. Int J Geriatr Psychiatry 2006;21: 432-441.
40. Rezvanfard M, Ekhtiari H, Noroozian M, Rezvanifar A, Nilipour R, Karimi Javan G. The Rey Auditory Verbal Learning Test: Alternate forms equivalency and reliability for the Iranian adult population (Persian version). Arch Iran Med 2011;14:104-109.